E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
locally advanced rectal cancer with high risk of recurrence |
|
E.1.1.1 | Medical condition in easily understood language |
locally advanced rectal cancer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
feasibility and tolerance of a preoperative induction chemotherapy in combination with Bevacizumab followed by combined radiochemotherapy with Capecitabine for patients with locally advanced rectal carcinoma |
|
E.2.2 | Secondary objectives of the trial |
Assessment of the respond rate (R0 rate, downstaging of the T- and N-stage), evaluation of the postoperative morbidity according to Accordeon at the day of release from the inpatient stay |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Age 18-80 years
• Histologic confirmation of rectal andenocarcinoma stage cT3 (≤ 5mm to the mesorectal fascia)/cT4( primary curative intention)NxM0
• No former chemotherapy, no former radiotherapy of the pelvic, no former tumour resection of a rectal carcinoma
• General condition WHO grade 0-2
• Adequate bone marrow reserve ( leucocytes ≥3 000/µl, thrombocytes ≥100 000/µl)
• Adequate renal function (creatinine ≤ 1,5 mg/dl, creatinine clearence > 50ml/min (Cockroft and Gault formula))
• Adequate liver function (bilirubin ≤1,5x ULN, GOT and GPT ≤3,5x ULN)
• Exclusion of pregnancy for women with childbearing potential (negative pregnancy test urine or serum)
• Female patients with childbearing potential and male patients that are not surgically sterile must be practicing a medically acceptable contraceptive regimen while on study treatment until 3 months after the end of the study (e.g. oral contraceptives, condom, intrauterine device)
• Life expectancy of at least 3 months
• INR and aPTT ≤ 1,5 x LLN
• Provision of signed informed consents before registration
|
|
E.4 | Principal exclusion criteria |
• Rectal carcinoma stage cT3 (> 5mm from the mesorectal fascia) all stages <cT3, M1
• Other malignant tumours within the last 5 years except cervical carcinoma in situ and basal cell carcinoma of the skin
• General contraindication or known hypersensitivity against Bevacizumab, Capecitabine and Oxaliplatin
• Not malignant diseases for which treatment with radiotherapy, resection of the rectum and treatment with chemotherapy (Bevacizumab, Capecitabine) is contraindicated:
uncontrolled hypertension (systolic > 150 mmHG and/or diastolic > 100 mmHG) or clinically significant (e.g. active) cardiovascular diseases: CVA (cardiovascular accident)/ apoplectic insult (≤ 6 months prior to registration), myocardial infarction (≤ 6 months prior to registration), unstable angina pectoris, CHF(congestive heart failure) with NYHA (New York heart Association) Grade II or higher, cardiac arrhythmia requiring therapy, hepatic diseases, significant neurologic or psychiatric disorders
• Florids, serious infection at registration
• Peripheral neuropathy (NCI CTCAE v 4.0 ≥ grade 1)
• Juridically limited contractual capability, indication of neurological or psychiatric disease which constrains upon investigators opinion the patients capability to adhere to the study routines
• Major surgical procedure within 28 days prior start of the study, open wounds
• Significant traumatic injury, bone fracture, unhealed wounds
• Patients with spinal cord compression or metastases in the central nervous system
• Indication of bleeding diathesis or coagulopathy
• Intake of anticoagulant or thrombolytic agents and/or Aspirin > 325 mg/d within 10 days prior to registration
• Current or recent (within 10 days prior to treatment start) therapy with full dosed anticoagulants. Preventive therapy is allowed.
• Previous thromboembolic or haemorrhagic events within 6 months prior to registration
• Previous abdominal fistulas, gastro-intestinal perforation or intra-abdominal abscesses within 6 months prior to registration
• Treatment with another investigational drug within 28 days prior to registration
• Patients with malabsorbtion syndrome or difficulties in swallowing
• Indication of poor compliance of the patient
• Pregnant or breast-feeding women
• Proteinuria: Dipstick <2+. If the Dipstick is ≥2+ protein has to be estimated in the 24 hours urine. The value should not be higher then 1g/24 hours. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
termination of therapy, occurrence of toxicity |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- termination of therapy: before surgery (after conclusion of therapy phase)
- occurence of toxicity: until the timepoint of discharge of patient |
|
E.5.2 | Secondary end point(s) |
downstaging of the T- and N-stage, occurrence of pathological complete remission, post-surgery morbidity according to Accordion |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- downstaging of the T- and N-stage, occurrence of pathological complete remission: at the timepoint of surgery
- morbitdity: at the timepoint of discharge of patient |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
feasibility and tolerance of a preoperative induction chemotherapy |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study = day of release from the inpatient stay after surgery |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |